Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Altimmune Inc ALT

Healthcare Biotechnology
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALT)

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

GlobeNewswire 6 days ago

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire 9 days ago

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 10 days ago

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

GlobeNewswire 10 days ago

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

GlobeNewswire November 7, 2024

Altimmune to Participate at Two Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

GlobeNewswire November 4, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

GlobeNewswire October 15, 2024

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

GlobeNewswire October 1, 2024
View More News ››

Opinion & Analysis (NDAQ:ALT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALT)

Altimmune Announces Publication of Clinical Study of Pemvidu

BREAKING NEWS: $ALT Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver...
whytestocks - July 25, 2024

Racing to finnish

Up up up up
Nibinator - December 6, 2023

Can the President Overrule the FDA on Vaccines?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020

no and no

NO CURE FOR CANCER since 1981 https://en.wikipedia.org/wiki/Terry_Fox_Run NO CURE FOR HIV https://www.hiv.gov/hiv-basics/hiv...
starman1975 - May 26, 2020

I can’t get over today’s volume!

Can someone explain to me how this stock went from 49.00 down to 1.70 in a year? They seem to have lots of cash on hand as well.
SeekAlpha81 - March 19, 2019

breakout alert for this one

it's going up big time,so glta shareholders.
coolfooldumbguy - March 19, 2019
View more Bullboard ››

Theralase Technologies Inc.

Theralase Technologies Inc.

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research ...
View More »